Epitopea

📢 We’re hiring! Join the Epitopea team as our Lab Manager! 📍 Location: Montréal   Epitopea is looking for a highly organized Lab Manager with experience in laboratory management and immunology #research. This is an excellent opportunity for someone who is looking to contribute to innovative scientific research.   Key Responsibilities: 🔹 Onboarding and training new employees 🔹 Managing inventory, supplies, and equipment 🔹 Writing and revising laboratory SOPs, and maintaining lab records in compliance with industry regulations 🔹 Coordinating animal model use and performing assays 🔹 Supporting data presentation and analysis for senior management   Qualifications: 🔸 Bachelor’s or Master’s degree in Biology, Immunology, or a related field 🔸 Hands-on experience with immunology techniques such as cell culture, T cell expansion, flow cytometry, and Elispot assays (preferable) 🔸 Familiarity with in vivo models and experimental protocols 🔸 Strong organizational skills and attention to detail   Apply Today!
If you’re passionate about advancing cancer immunotherapies, we want to hear from you! 📧 For more details and to apply, visit our careers page: https://lnkd.in/eGPMz_Fx   #Biotech #CancerResearch #LabManager #Innovation #Oncology #JobOpening

📢 Nous recrutons ! Rejoignez l'équipe d'Epitopea en tant que responsable de laboratoire ! 📍 Lieu : Montréal   Epitopea recherche un responsable de laboratoire très organisé, ayant de l'expérience dans la gestion de laboratoire et dans le domaine de la recherche en immunologie. Il s'agit d'une excellente opportunité pour quelqu'un qui souhaite contribuer à la recherche scientifique innovante.   Principales responsabilités : 🔹 Acceuil et formation des nouveaux employés 🔹 Gestion des stocks, des fournitures et des équipements de laboratoire 🔹 Rédaction et révision des procédures opérationnelles normalisées du laboratoire et tenue des registres du laboratoire conformément aux réglementations de l'industrie 🔹 Coordination de l'utilisation des modèles animaux et réalisation des essais 🔹 Soutien à la présentation et à l'analyse des données pour la direction générale   Qualifications : 🔸 B.Sc. ou M.Sc en biologie, immunologie ou dans un domaine connexe 🔸 Expérience pratique des techniques d'immunologie telles que la culture cellulaire, l'expansion des lymphocytes T, la cytométrie en flux et les tests Elispot (de préférence) 🔸 Connaissance des modèles in vivo et des protocoles expérimentaux 🔸 Solides compétences organisationnelles et souci du détail   Postulez dès aujourd'hui ! Si vous êtes passionné par le développement des immunothérapies contre le cancer, nous voulons vous rencontrer ! 📧 Pour plus de détails et pour postuler, consultez notre page Carrières : https://lnkd.in/esGuQ53t #Biotech #CancerResearch #LabManager #Innovation #Oncology #JobOpening

Northern RNA Inc., a contract drug manufacturing organization (CDMO) specializing in GMP manufacturing of RNA-based vaccines and therapeutics, and Epitopea, a transatlantic cancer immunotherapeutics company developing accessible off-the-shelf RNA-based immunotherapies, today announced they have entered into a strategic collaboration that will see Northern RNA provide its cutting-edge biomanufacturing expertise to support the development of Epitopea’s innovative RNA-based immunotherapies targeting solid and hematological cancers. #CDMO #RNA #mRNA #LNP #Lipids #Oligo #Biomanufacturing #GMP #DrugDevelopment #CancerTherapy #Immunotherapy #Oncology #ManufacturingABetterFuture

🔬 Epitopea Announces License and Research Collaboration with MSD We are excited to announce a research collaboration and license agreement with MSD to identify Cryptigen™ tumor-specific antigens (TSAs) in an undisclosed solid tumor type. Epitopea has been at the forefront of identifying Cryptigen™ TSAs, a unique class of shared, non-mutated, aberrantly expressed tumor antigens derived from previously overlooked "junk DNA." As part of the collaboration, we will identify and provide novel, immunogenic Cryptigen™ TSAs to help advance the development of off-the-shelf cancer immunotherapies. MSD will have the exclusive right to develop and commercialize therapeutics derived from this collaboration. In return, Epitopea will receive an undisclosed upfront payment and is eligible for milestone payments to total up to $300M per product. 🔗 Read the Press Release: [ENG] https://lnkd.in/eCJXbbW9 [FR] https://lnkd.in/ewg_6Mte #Biotech #Innovation #Immunotherapy #Oncology #CancerResearch

We’re proud to welcome Dr. Klaus Edvardsen as Chief Medical Officer at Epitopea! Klaus brings extensive expertise in oncology drug development, having led clinical and regulatory programs at Nykode Therapeutics, CureVac, and Merck Healthcare KGaA. During his tenure at AstraZeneca, he played a pivotal role in the approvals of blockbuster medicines, shaping the oncology treatment landscape. With Klaus’s leadership, we are focused on advancing our pipeline of RNA-based cancer immunotherapies into the clinic. 🔗 Read the full press release:   [ENG] https://lnkd.in/g5WQYKV6 [FR ] https://lnkd.in/gCGicdYC #Biotech #Oncology #CancerImmunotherapy #Leadership #Innovation

We’ll be in San Francisco during J.P. Morgan Week, January 13-16, 2025, and are eager to connect with partners, investors, and leaders in the biotech community! Meet Alan Rigby, CEO, and Steven Klein, CBO, to explore how Epitopea is advancing its next-generation, tumour-selective immunotherapies to deliver durable, tumour-specific immune responses. Following our recent $31M pre-Series A financing, we are accelerating our transition to the clinic and seeking to drive impactful partnerships to bring life-changing therapies to patients. This is a great opportunity to discuss potential collaborations to develop innovative immunotherapies based on our innovative CryptoMap™ platform and propriety Cryptigen™ tumour-specific antigens, which are uniquely shared across patients with hard-to-treat cancers. 📧 Schedule a meeting: info@epitopea.com #Biotech #Innovation #Immunotherapy #CancerResearch #Oncology

We’re pleased to announce a new collaboration with Genevant Sciences, a leader in lipid nanoparticle (LNP) technology, to enable the development of a next-generation, off-the-shelf RNA-based immunotherapy. This partnership will combine Epitopea’s proprietary Cryptigen™ tumor-specific antigens with Genevant’s world-class LNP delivery technology, to extend the durability of patient outcomes in a solid tumor indication with limited treatment options. This collaboration accelerates our journey toward the clinic and strengthens our commitment to bringing innovative, tumor-selective immunotherapies to patients in need worldwide. 🔗Read the Press Release: [ENG] https://lnkd.in/gxA4gz8G [FR] https://lnkd.in/gk-u4QQM #Biotech #Innovation #Immunotherapy #Oncology #CancerResearch

Meet Alan Rigby and Steven Klein at the upcoming Personalized Cancer Vaccine Summit in Boston, December 3-5! As pioneers in developing accessible, off-the-shelf RNA-based immunotherapies, we target Cryptigen™ TSAs—tumor-specific antigens uniquely expressed across patients with hard-to-treat cancers. Using our proprietary CryptoMap™ platform, we’ve identified an extensive library of these cryptic antigens to drive durable, tumor-selective immune responses. Following our recent USD $31M pre-Series A financing, we’re rapidly advancing our innovative therapies towards the clinic, and are looking forward to joining the cancer vaccine community in Boston at this event! 🔗Event info: https://lnkd.in/e5ebTCif 📧Meet us there: info@epitopea.com Hanson Wade Group #biotech #pharma #innovation #cancerresearch #oncology

Delighted to share recent coverage by Mike Scialom at the Cambridge Independent on our successful USD $31M pre-Series A financing, a milestone that supports our mission to deliver innovative RNA-based immunotherapies to the clinic by 2026. Our proprietary CryptoMap™ platform enables us to unlock Cryptigen™ TSAs—tumor-specific antigens hidden within cancer’s ‘junk’ DNA—advancing accessible, off-the-shelf solutions for hard-to-treat cancers. 🔗Read the article: https://lnkd.in/e4mMitv5 #biotech #pharma #innovation #cancerresearch #oncology #financing

A major milestone for Epitopea - we’re excited to announce the closing of our USD $31 million pre-Series A financing, bringing our total raised to over USD $45 million. This investment, supported by both new and existing investors, accelerates the development of our next-generation, tumor-selective, RNA-based immunotherapies targeting Cryptigen™ antigens. This funding will help drive Epitopea’s accelerated optimization of its off-the-shelf RNA immunotherapies and its transition to a clinical-stage company delivering differentiated immunotherapies focused on enhancing the durability of clinical response for cancer patients. 🔗 Read the Press Release: [ENG] https://lnkd.in/etU9YDA8 [FR] https://lnkd.in/e9xx6ytY Our investors: Investissement Québec, adMare BioInnovations, Jonathan Milner, Advent Life Sciences, CTI Life Sciences Fund, Cambridge Innovation Capital Fonds de solidarité FTQ, Harrington Discovery Institute at University Hospitals , IRICoR, Novateur Ventures Inc. #Biotech #Innovation #Pharma #Research #Cancer